Inogen, Inc (INGN) EVP Sells $1,423,950.00 in Stock
Inogen, Inc (NASDAQ:INGN) EVP Alison Bauerlein sold 15,000 shares of the stock in a transaction dated Tuesday, October 10th. The stock was sold at an average price of $94.93, for a total transaction of $1,423,950.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Alison Bauerlein also recently made the following trade(s):
- On Thursday, August 10th, Alison Bauerlein sold 6,667 shares of Inogen stock. The stock was sold at an average price of $92.64, for a total transaction of $617,630.88.
Inogen, Inc (NASDAQ:INGN) traded up 1.32% on Thursday, hitting $94.90. 101,855 shares of the stock were exchanged. Inogen, Inc has a 52-week low of $50.24 and a 52-week high of $105.35. The company has a 50-day moving average price of $98.06 and a 200-day moving average price of $90.62. The firm has a market cap of $1.97 billion, a PE ratio of 82.38 and a beta of 0.99.
Inogen (NASDAQ:INGN) last issued its quarterly earnings data on Thursday, August 3rd. The medical technology company reported $0.38 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.28 by $0.10. Inogen had a return on equity of 12.45% and a net margin of 10.36%. The company had revenue of $64.10 million during the quarter, compared to analyst estimates of $59.99 million. During the same quarter in the previous year, the firm earned $0.25 earnings per share. Inogen’s revenue was up 17.4% on a year-over-year basis. On average, equities research analysts anticipate that Inogen, Inc will post $1.21 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This report was originally reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/10/12/inogen-inc-ingn-evp-sells-1423950-00-in-stock.html.
Hedge funds and other institutional investors have recently modified their holdings of the company. Ameritas Investment Partners Inc. purchased a new position in shares of Inogen during the first quarter worth about $109,000. Schroder Investment Management Group purchased a new position in shares of Inogen during the second quarter worth about $132,000. Victory Capital Management Inc. grew its holdings in shares of Inogen by 36.1% during the first quarter. Victory Capital Management Inc. now owns 1,729 shares of the medical technology company’s stock worth $134,000 after purchasing an additional 459 shares in the last quarter. Sei Investments Co. grew its holdings in shares of Inogen by 38.1% during the second quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock worth $153,000 after purchasing an additional 443 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Inogen during the first quarter worth about $203,000.
A number of equities research analysts have issued reports on INGN shares. Zacks Investment Research downgraded shares of Inogen from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 11th. J P Morgan Chase & Co increased their price objective on shares of Inogen to $102.00 and gave the stock an “overweight” rating in a research note on Monday, June 26th. Piper Jaffray Companies reiterated a “hold” rating and set a $90.00 price objective on shares of Inogen in a research note on Tuesday, September 12th. Needham & Company LLC reiterated a “buy” rating and set a $108.00 price objective on shares of Inogen in a research note on Friday, September 1st. Finally, BidaskClub upgraded shares of Inogen from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 8th. Four investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $90.80.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.